The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral Therapy
Abstract
Introduction Abbreviations used in this article: AIDS, acquired immunodeficiency syndrome, ALT, alanine aminotransferase, CMV, cytomegalovirus, CSF, cerebrospinal fluid, HAART, highly active antiretroviral therapy, HBV, hepatitis B virus, HCV, hepatitis C virus, HIV, human immunodeficiency virus, IRIS, immune reconstitution inflammatory syndrome, MAC, Mycobacterium avium complex, MTB, Mycobacterium tuberculosis, PML, progressive multifocal leukoencephalopathy The discovery of effective therapy for human immunodeficiency virus (HIV) infection has improved the outlook for patients with the acquired immunodeficiency syndrome (AIDS) (75,88,115,121,134). Since the introduction of highly active antiretroviral therapy (HAART), there has been a decrease in the incidence of opportunistic infections among HIVinfected patients along with a corresponding reduction in the mortality rate (7,30,45,102,117). The basis for these improvements appears to be a result of partial recovery of the host’s immune system. Suppression of viral replication by antiretroviral therapy allows for the reappearance of immune effector cells, that in turn, provide vital protection against opportunistic pathogens (15,32,92,95,132). However beneficial HAART has been, experience during the past several years has disclosed the emergence, in a small proportion of cases, of a unique set of complications. Soon after treatment is begun, some patients experience clinical deterioration due to restoration of their capacity to mount an inflammatory immune response against both infectious and noninfectious antigens. This phenomenon which carries such labels as the immune reconstitution syndrome (IRS) and immune restoration disease (IRD), has been described for a wide variety of infectious pathogens (26,36,46). The manifestations of this syndrome are diverse and depend on the particular infectious agent involved. Given that an increased inflammatory response underlies its presentation, we propose the name immune reconstitution inflammatory syndrome (IRIS). Autoimmune diseases that occur following institution of HAART may also be considered as part of the same process. For the purpose of this review, IRIS is defined as a paradoxical deterioration in clinical status attributable to the recovery of the immune system during HAART. Recognition of this entity is crucial, for successful treatment relies on alleviation of the patient’s symptoms without compromising antiretroviral or antimicrobial therapy. In this article, we review the present understanding of the basic science underlying IRIS, with illustrative examples from our case series, and review the existing clinical literature. Patients and Methods Patient identification and chart review; case definition After IRIS had been discussed at several teaching conferences in the Texas Medical Center, members of the full-time faculty, Department of Medicine (Infectious Disease Section), Baylor College of Medicine, were asked to identify patients with clinical scenarios compatible with this syndrome. The medical records of these patients were then reviewed by 1 of the investigators. Patients were included if they fulfilled the following 4 criteria: The patient had a diagnosis of AIDS; Treatment with anti-HIV medicines (usually, but not necessarily including a protease inhibitor) had led to an increase in CD4+ T lymphocytes and a decrease in HIV-1 viral load if measured. [Some cases of IRIS preceded the widespread use of HIV-1 viral loads. All cases where viral loads are not mentioned occurred during this era.]; Symptoms consistent with an infectious/inflammatory (autoimmune) condition appeared while on antiretroviral therapy, and; These symptoms could not be explained by a newly acquired infection, by the expected clinical course of a previously recognized infectious agent, or by side effects of therapy. Literature review We performed a computer-based search (MEDLINE, National Library of Medicine, Bethesda, MD; years 1996–2001, AIDSLINE, and AIDS conferences). Key words used in the search were immune restoration disease, immune reconstitution, immunoreconstitution, immune restitution, HAART, paradoxical reaction, HIV, and AIDS. The citations in all identified articles were evaluated, and all titles not previously found via the computerized search that contained the key words were reviewed. In addition, multiple Internet search engines were used to identify conferences related to AIDS, and papers presented at these conferences were reviewed. Articles published from 1996 until April 2001 that described various opportunistic infections and syndromes were also reviewed to elicit reports consistent with this syndrome. Pathophysiology of Immune Reconstitution with HAART Most studies evaluating HAART have utilized the combination of 1 protease inhibitor or nonnucleoside reverse transcriptase inhibitor plus 2 nucleoside analogue inhibitors. Following the initiation of such treatment, the levels of HIV RNA usually fall rapi
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Changes in thymic function with age and during the treatment of HIV infection
Douek, D. C., McFarland, R. D., Keiser, P. H., Gage, E. A., Massey, J. M., Haynes, B. F., Polis, M. A., Haase, A. T., Feinberg, M. B., Sullivan#, J. L., et al. (1998) · Nature · doi:10.1038/25374 · Cited by 1,893
Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debré, P., & Leibowitch, J. (1997) · Science · doi:10.1126/science.277.5322.112 · Cited by 1,785
Practice Guidelines for the Management of Cryptococcal Disease
Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E., & Mycoses Study Group Cryptococcal Subproject (2000) · Clinical Infectious Diseases · doi:10.1086/313757 · Cited by 1,105
Paradoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS
NARITA, M., ASHKIN, D., HOLLENDER, E. S., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9712001 · Cited by 608
Li, T., Tubiana, R., Katlama, C., Calvez, V, Mohand, H. A., & Autran, B. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10291-4 · Cited by 544
Bozzette, S. A., Sattler, F. R., Chiu, J., Wu, A. W., Gluckstein, D., Kemper, C., Bartok, A., Niosi, J., Abramson, I., Coffman, J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011223232104 · Cited by 495
Graybill, J. R., Sobel, J., Saag, M., van der Horst, C., Powderly, W., Cloud, G., Riser, L., Hamill, R., Dismukes, W., & NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups (2000) · Clinical Infectious Diseases · doi:10.1086/313603 · Cited by 486
Self-citationLederman, M. M., Connick, E., Landay, A., Kuritzkes, D. R., Spritzler, J., St. Clair, M., Kotzin, B. L., Fox, L., Heath Chiozzi, M., Leonard, J. M., et al. (1998) · Journal of Infectious Diseases · doi:10.1086/515591 · Cited by 425
Komanduri, K. V., Viswanathan, M. N., Wieder, E. D., Schmidt, D. K., Bredt, B. M., Jacobson, M. A., & McCune, J. M. (1998) · Nature Medicine · doi:10.1038/nm0898-953 · Cited by 389
Cited by
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
Meintjes, G., Lawn, S. D., Scano, F., Maartens, G., French, M. A., Worodria, W., Elliott, J. H., Murdoch, D., Wilkinson, R. J., Seyler, C., et al. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70184-1 · Cited by 745
Shelburne, S. A., Visnegarwala, F., Darcourt, J., Graviss, E. A., Giordano, T. P., White, A. C., & Hamill, R. J. (2005) · AIDS · doi:10.1097/01.aids.0000161769.06158.8a · Cited by 632
Self-citationRatnam, I., Chiu, C., Kandala, N. B., & Easterbrook, P. J. (2006) · Clinical Infectious Diseases · doi:10.1086/499356 · Cited by 355
Tuberculosis in HIV-infected patients: a comprehensive review
Aaron, L., Saadoun, D., Calatroni, I., Launay, O., Mémain, N., Vincent, V., Marchal, G., Dupont, B., Bouchaud, O., Valeyre, D., et al. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00758.x · Cited by 330
Metadata
- Authors
- SHELBURNE, S. A., HAMILL, R. J., RODRIGUEZ-BARRADAS, M. C., GREENBERG, S. B., ATMAR, R. L., MUSHER, D. M., GATHE, J. C., VISNEGARWALA, F., & TRAUTNER, B. W.
- Venue
- Medicine
- Published
- 2002-05
- Volume
- 81
- Issue
- 3
- Pages
- 213-227
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W1975889256
- Cited by
- 654
- References
- 74
- FWCI
- 26.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral Therapy. https://app.cochat.ai/papers/10.1097/00005792-200205000-00005
- The paper
- SHELBURNE, S. A., HAMILL, R. J., RODRIGUEZ-BARRADAS, M. C., GREENBERG, S. B., ATMAR, R. L., MUSHER, D. M., GATHE, J. C., VISNEGARWALA, F., & TRAUTNER, B. W. (2002). Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral Therapy. Medicine. https://doi.org/10.1097/00005792-200205000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.